Atlas Venture Fund XII, L.P. - 15 Jul 2022 Form 4 Insider Report for Aerovate Therapeutics, Inc. (JBIO)

Reporting relationship: 10%+ Owner
Issuer ticker: JBIO
Reported as of: 15 Jul 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 19 Jul 2022, 17:28:43 UTC
Prior SEC filing: 04 Apr 2022
Next SEC filing: 07 Aug 2025
Source filing: View source filing
Reporting owner signature: Atlas Venture Fund XII, L.P. By: Atlas Venture Associates XII, L.P., Its: General Partner By: Atlas Venture Associates XII, LLC, Its General Partner, By: /s/ Ommer Chohan

Filing notes and source

Key filing fact

Atlas Venture Fund XII, L.P. filed Form 4 for Aerovate Therapeutics, Inc. (JBIO) on 19 Jul 2022.

Key facts

This page summarizes Atlas Venture Fund XII, L.P.'s Form 4 filing for Aerovate Therapeutics, Inc. (JBIO).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 19 Jul 2022, 17:28.

Change

Previous filing in this sequence was filed on 04 Apr 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AVTE transaction

Common Stock

Other

Transaction value: $0
Shares: -310,388
Change %: -12%
Price: $0.000000
Shares after: 2,327,909
Date: 15 Jul 2022
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Atlas Venture Fund XII, L.P. is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 1 footnote

Footnote F1

Represents a pro rata distribution, and not a purchase or sale of securities, by Atlas Venture Fund XII, L.P. ("Atlas Venture Fund XII") to its general partner and limited partners without additional consideration. This distribution was effected pursuant to a plan adopted by Atlas Venture Fund XII pursuant to Rule 10b5-1 on November 24, 2021.